Advertisement
Bio-Gene Technology Limited

Bio-Gene Technology Limited (BGT.AX) Stock Competitors & Peer Comparison

See (BGT.AX) competitors and their performances in Stock Market.

BGT.AXASX
HealthcareBiotechnology
$0.02
$0.00(0.00%)
Australian Market opens in 50h 1m
Advertisement

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
BGT.AXA$0.02+0.00%5.1M-2.67-A$0.01N/A
CSL.AXA$117.91+2.76%56.7B12.73A$9.30+3.60%
TLX.AXA$17.15+3.44%5.8B-614.22-A$0.03N/A
MSB.AXA$2.05+4.86%2.6B-13.72-A$0.15N/A
NEU.AXA$16.99-4.28%2.2B75.14A$0.23N/A
PYC.AXA$1.62-4.15%979.5M-36.84-A$0.05N/A
OPT.AXA$0.60+0.00%820.8M6.14A$0.10N/A
CUV.AXA$10.23-0.49%525.3M16.17A$0.64+0.48%
RAC.AXA$2.18-1.80%431.4M-106.28-A$0.02N/A
SPL.AXA$0.72+2.14%298.9M112.70A$0.01N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

BGT.AX vs CSL.AX Comparison July 2026

BGT.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGT.AX stands at 5.1M. In comparison, CSL.AX has a market cap of 56.7B. Regarding current trading prices, BGT.AX is priced at A$0.02, while CSL.AX trades at A$117.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGT.AX currently has a P/E ratio of -2.67, whereas CSL.AX's P/E ratio is 12.73. In terms of profitability, BGT.AX's ROE is -1.40%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, BGT.AX is more volatile compared to CSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BGT.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions